patientswww.38.com

www.38.com  时间:2021-03-21  阅读:()
WORLDJOURNALOFSURGICALONCOLOGYCheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38OpenAccessRESEARCHBioMedCentral2010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
ResearchBonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerKwok-LeungCheung*1,RayKIles2andJohnFRRobertson1AbstractBackground:Foetalantigen2(FA-2),firstisolatedintheamnioticfluid,wasshowntobethecirculatingformoftheaminopropeptideofthealpha1chainofprocollagentypeI.
SerumconcentrationsofFA-2appearedtobeelevatedinanumberofdisordersofbonemetabolism.
Thispaperisthefirstreportofitsroleasamarkerofbonemetabolisminmetastaticbreastcancer.
Methods:SerumFA-2concentrationsweremeasuredbyradioimmunoassayin153womenwithdifferentstagesofbreastcancerandin34normalcontrols.
Results:SerumFA-2wassignificantlyelevatedinwomenwithbonymetastases(p5cmand/orotherfeaturesoflocallyadvanceddisease(eginflammatorycancer,fixationtochestwall,ulceratingtumour)withoutanyevidenceofdistantmetastasesandattendedtheLAPCClinic.
Bloodsamplesweretakenwhenthetumourwasstillinsitu.
*Correspondence:kl.
cheung@nottingham.
ac.
uk1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKFulllistofauthorinformationisavailableattheendofthearticleCheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page2of44.
Womenwithadvancedbreastcancer(ABC)-ThesewerewomenattendingtheABCClinicandallhaddistantmetastases.
PreparationofSerumSamplesBloodobtainedbyvenesectionwascollectedinplaintubes,allowedtostandforatleast30minutesandthencentrifugedat2,500revolutionsperminutefor20min-utes.
Serumwaspipettedinto1-mlaliquotsandstoredinthefreezerat-20°C.
FA-2AssaysTheserumsamplesweretransportedat-20°CtotheWil-liamsonLaboratoryatStBartholomew'sHospital.
FA-2radioimmunoassayswerecarriedoutaspreviouslydescribed[3].
Theassayswereperformedinablindman-nerwithaliquotstaggedwithasamplenumberwithoutanyclinicalinformation.
StatisticalMethodsStatisticalanalysiswascarriedoutusingthestandardisedbiomedicalcomputerprogrammeSPSSforWindows(SPSSUKLtd).
TheANOVAtestwasusedformultiplegroupcomparisonofthemeanvalues.
Statisticallysignif-icantdifferencewasdefinedbyp<0.
05.
TheauthorsconfirmthatapprovalhasbeenobtainedfromLocalResearchEthicsCommitteetoconductthisstudyonbloodmarkersinbreastcancer.
ResultsThemeanvaluesofserumFA-2levelsinallfourgroupsofwomenweresummarisedinTable1.
Therewasnodif-ferenceinFA-2levelsamongnormalwomenandwomenwithbreastcancerwhichwasstillconfinedtothebreast(iePBCandLAPC)(Tables1and2).
Nevertheless,whenallstagesofcancerweretakenintoconsideration,FA-2levelsappearedtobesignificantlyelevatedincancerpatientswhencomparedtonormalwomenandthiswasduetomarkedelevationinwomenwithmetastaticbreastcancer(Table2).
WomenwithmetastaticdiseasehadamuchhighervalueofFA-2thanthosewithout(Table3)andthiswasduetothesignificantelevationofFA-2inwomenwithbonymetastases(Figure1).
Inconclusion,theresultssuggestedthatFA-2wassig-nificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
DiscussionBloodtumourmarkersinbreastcancerhavebeenknownfordecades.
Incontrasttomarkersintheprimarytumourtissue,bloodtumourmarkersreflectadynamicsituationandtheirmeasurementscanberepeatedasrequired.
Theuseofbloodtumourmarkersismostestab-lishedinthediagnosisandmonitoringofsymptomaticmetastaticdisease.
InthediagnosisofmetastaticbreastTable1:MeanValuesofFA-2forAllWomenSamplecategoryNMean±SD(AU/ml)Normal340.
21±0.
09PBC350.
18±0.
08LAPC380.
33±0.
67ABC800.
85±1.
34All187Figure1ComparisonofFA-2levelsbetweenboneandnon-bonemetastases.
SamplecategoryNMean±SD(AU/ml)pvalueNon-bonymetastasesBonymetastases*20530.
37±0.
360.
91±0.
940.
0149*Includingpatientswithbothskeletalandextra-skeletalmetastases.
non-boneboneMetastases0.
001.
002.
003.
004.
00AUperml$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page3of4cancer,CA15.
3assayhasbeenshowntobesuperiorwithCEAbeingthenextmostclinicallyusefulmarker[4].
ThesensitivitycanbefurtherincreasedwhenapanelofthreemarkersieCA15.
3,CEAandESRareused[5-8].
Whiletheusefulnessofbloodtumourmarkersiswellestab-lishedinadvancedbreastcancer,activeresearch,bothclinicalandlaboratory,isongoingtorefinethemeasure-mentsofexistingmarkers,toexplorenewermarkersandtodevelopbettermarkerassays,aimingtooptimisetheiruseinadvanceddiseaseaswellastoexploittheiruseinscreeninganddiagnosisofearlyprimarybreastcancer.
Markersofbonemetabolismareamongthenewmark-erswhicharebeinginvestigated.
Traditionalmarkersofbonemetabolismincludeserumalkalinephosphatase,serumandurinarycalcium,urinaryhydroxprolineetc.
Markersofcollagensynthesishavebeenevaluatedasbonemarkersformetastaticbonediseaseduetobreastcancer.
ThemostabundantproteininboneistypeIcolla-gen.
Duringitsformationtwoextensionpeptidesfromtheprocollagenmolecule,carboxy-andaminoterminalpropeptides(PICPandPINP)arereleasedintothecircu-lationandtheyaremarkersofboneformation.
TypeIcol-lagencarboxyterminaltelopeptide(ICTP)isformedduringbonecollagenbreakdownandisagainliberatedintothecirculation.
Itslevelintheserumthereforereflectsboneresorption.
ICTPhasahighspecificitythoughrelativelylowsensitivityandisthebestbonemetabolismmarkerevaluated[9,10].
Furtherstudiestoevaluatethecost-effectivenessofmeasuringthesemark-ersandtoexplorenewermarkersofbonemetabolismarerequired[11].
Afteritsisolationfromtheamnioticfluid,FA-2wasfoundelevatedinserumofpatientswithrenalosteo-dystrophy[12]andwithprimaryhyperparathyroidism[13].
PatientswiththelatterhadFA-2levelsdroppedsig-nificantlyaftersurgicalremovaloftheparathyroidglands[13].
AllthesehavesuggestedFA-2asapossiblemarkertoevaluatebonemetabolism.
EvidenceofFA-2synthesisbyfoetalosteoblastsshownusingimmunohistochemicalstainingtechniqueshassubstantiatedthispotentialrole[14].
Thepresentstudyisthefirstreportofthemeasure-mentofserumFA-2indifferentstagesofbreastcancer.
ItshowedthatserumFA-2waselevateddistinctlyinwomenwithbonymetastases.
Itslevelsweresignificantlylowerinwomenwithoutmetastasesincludingnormalcontrols.
Thefactthatthemeanvalueinwomenwithmetastaseswassignificantlyhigherthatinwomenwith-outcouldentirelybeexplainedbytheinclusionofwomenwithbonymetastasesintheformergroup.
Themeanvalueinwomenwithnon-bonymetastaseswasvirtuallysimilartothatofthosewithoutmetastases.
InessenceserumFA-2hasbeenfoundtobesignificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
ThesepreliminarydatapointoutthatFA-2isapotentialhelpfulbloodmarkerforbonymetastasesfrombreastcancer.
ItwouldthereforeappearthatserumFA-2mea-surementmaybeusefulinthediagnosisofbonymetasta-ses.
Whetheritwillbeshowntobesuperiortoexistingmarkersand/orradiologicalmethodsremainstobeeluci-dated.
Theotherroleoftumourmarkermeasurementisinthemonitoringoftherapy.
Inthepresenterawhentheuseofbisphosphonateshasbeenpopularisedinthemanage-mentofbonemetastasesforbreastcancer,markersofbonemetabolismmightprovideameasurementoftheeffectofsclerosisonthebonewhileconventionalbloodmarkerssuchasCA15.
3andCEAreflecttheefficacyofanti-cancertherapyontumourmass.
InthesewaysnewTable2:ComparisonofFA-2LevelsbetweenDifferentGroupsSamplecategorypvaluePBC0.
19LAPCSamplecategorypvaluePBC0.
0037ABCSamplecategorypvalueLAPC0.
0243ABCTable3:ComparisonofFA-2LevelsbetweenMetastaticandNon-MetastaticCancersSamplecategoryNMean±SD(AU/ml)pvalueNon-metastatic730.
26±0.
490.
0004Metastatic800.
85±1.
34Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page4of4markershaveacomplementaryratherthananexclusiveroleinthediagnosisandmonitoringofbreastcancer[11].
Giventhepreliminaryresultsfromthisobservationalstudywhichhasitsstatisticallimitationsduetoitssmallsize,furtherstudiesarethereforerequiredtodefineindetailstheexactvalueofserumFA-2measurementinbonymetastasesfrombreastcancer.
Comparisonwithconventionalmarkersoftumourmass(egCA15.
3,CEA)andknownnovelmarkersofbonemetabolism(egPICP,PINP,ICTP)(bothinthediagnosisandinthemonitoringofresponsetosystemictherapy),andidentificationofthepatternofchangesofserumFA-2levelsinrelationtobis-phosphonatetherapyandeventssuchashypercalcaemiaareareasthatneedtobeexploredbeforetheuseofFA-2couldbeincorporatedintodailyclinicalpractice.
AbbreviationsFA-2:Foetalantigen2;CA15.
3:Cancerantigen15.
3;CEA:Carcinoembryonicantigen;PBC:Primarybreastcancer;LAPC:Locallyadvancedprimarybreastcancer;ABC:Advancedbreastcancer;PICP:CarboxyterminalpropeptideoftypeIprocollagen;PINP:AminoterminalpropeptideoftypeIprocollagen;ICTP:TypeIcollagencarboxyterminaltelopeptide.
CompetinginterestsTheauthorsdeclarethattheyhavenocompetinginterests.
Authors'contributionsKLCperformedthestatisticalanalysisanddraftedthemanuscript.
AllpatientswereunderthecareofKLCandJFRRwhowereresponsibleforcollectingbloodsamplesandclinicaldata.
RKIwasresponsibleforcarryingouttheassayforFA-2.
JFRRconceivedofthestudy.
Allparticipatedinthedesign;readandapprovedthefinalmanuscript.
AuthorDetails1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKand2WilliamsonLaboratory,StBartholomew'sHospital,London,UKReferences1.
FayTN,JacobsI,TeisnerB,PoulsenO,ChapmanMG,StabileI,BohnH,WestergaardJG,GrudzinskasJG:Twofetalantigens(FA-1andFA-2)andendometrialproteins(PP12andPP14)isolatedfromamnioticfluid;preliminaryobservationsinfetalandmaternaltissues.
EurJObstetGynecolReprodBiol1988,29:73-85.
2.
TeisnerB,RasmussenHB,HojrupP,Yde-AndersonE,SkjodtK:Fetalantigen2:anamnioticproteinidentifiedastheaminopropeptideofthealpha1chainofhumanprocollagentypeI.
APMIS1992,100:1106-14.
3.
PriceKM,SilmanR,ArmstrongP,GrudzinskasJG:Developmentofaradioimmunoassayforfetalantigen2.
ClinChimActa1994,224:95-102.
4.
KleistSV,BombardieriE,BuraggiG,GionM,HertelA,HrG,Noujaima,SchwartzM,SenekowitschR,WittekindC:Immunodiagnosisoftumours.
EurJCancer1993,29A:1622-30.
5.
RobertsonJFR,PearsonD,PriceMR,SelbyC,BlameyRW,HowellA:Objectivemeasurementoftherapeuticresponseinbreastcancerusingtumourmarkers.
BrJCancer1991,64:757-63.
6.
DixonAR:Tumourmarkers-alogicalapproachtotheguidanceoftherapyinadvancedbreastcancerInDoctorofMedicineThesisUniversityofNottingham;1991.
7.
DixonAR,JnrupI,JacksonL,ChanSY,BadleyRA,BlameyRW:SerologicalmonitoringofadvancedbreastcancertreatedbysystemiccytotoxicusingacombinationofESR,CEA,andCA15.
3:factorfictionDiseaseMarkers1991,9:167-74.
8.
DixonAR,JacksonL,ChanSY,BadleyRA,BlameyRW:Continuouschemotherapyinresponsivemetastaticbreastcancer:arolefortumourmarkersBrJCancer1993,68:181-5.
9.
PlebaniM,BernardiD,ZaninottoM,DePaoliM,SecchieroS,SciacovelliL:Newandtraditionalserummarkersofbonemetabolisminthedetectionofskeletalmetastases.
ClinBiochem1996,29:67-72.
10.
TahtelaR,TholixE:SerumconcentrationsoftypeIcollagencarboxyterminaltelopeptide(ICTP)andtypeIprocollagencarboxy-andaminoterminalpropeptides(PICP,PINP)asmarkersofmetastaticbonediseaseinbreastcancer.
AnticancerRes1996,16:2289-93.
11.
CheungKL,GravesCRL,RobertsonJFR:Tumourmarkermeasurementsinthediagnosisandmonitoringofbreastcancer.
CancerTreatRev2000,26:91-102.
12.
BojeRasmussenH,TeisnerB,Bangsgaard-PetersenF,Yde-AndersenE,KassemM:Quantificationoffetalantigen(FA-2)insupernatantsofculturedosteoblasts,normalhumanserum,andserumfrompatientswithchronicrenalfailure.
NephrolDialTransplant1992,7:902-7.
13.
BojeRasmussenH,TeisnerB,GramJ,BrixenK,Yde-AndersenE,BollerslevJ:Serumlevelsoffetalantigen2inhyperthyroidismandprimaryhyperparathyroidism.
APMIS1992,100:894-900.
14.
TornehaveD,TeisnerB,RasmussenHB,ChemnitzJ,KassemM:Fetalantigen2(FA-2)inhumanfetalosteoblasts,culturedosteoblastsandosteogenicosteosarcomacells.
AntEmbryol(Berl)1992,186:271-4.
doi:10.
1186/1477-7819-8-38Citethisarticleas:Cheungetal.
,Bonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerWorldJournalofSurgicalOncology2010,8:38Received:16March2010Accepted:13May2010Published:13May2010Thisarticleisavailablefrom:http://www.
wjso.
com/content/8/1/382010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
WorldJournalofSurgicalOncology2010,8:38

妮妮云(119元/季)日本CN2 2核2G 30M 119元/季

妮妮云的知名度应该也不用多介绍了,妮妮云旗下的云产品提供商,相比起他家其他的产品,云产品还是非常良心的,经常出了一些优惠活动,前段时间的八折活动推出了很多优质产品,近期商家秒杀活动又上线了,秒杀产品比较全面,除了ECS和轻量云,还有一些免费空间、增值代购、云数据库等,如果你是刚入行安稳做站的朋友,可以先入手一个119/元季付的ECS来起步,非常稳定。官网地址:www.niniyun.com活动专区...

这几个Vultr VPS主机商家的优点造就商家的用户驱动力

目前云服务器市场竞争是相当的大的,比如我们在年中活动中看到各大服务商都找准这个噱头的活动发布各种活动,有的甚至就是平时的活动价格,只是换一个说法而已。可见这个行业确实竞争很大,当然我们也可以看到很多主机商几个月就消失,也有看到很多个人商家捣鼓几个品牌然后忽悠一圈跑路的。当然,个人建议在选择服务商的时候尽量选择老牌商家,这样性能更为稳定一些。近期可能会准备重新整理Vultr商家的一些信息和教程。以前...

CloudCone:洛杉矶MC机房KVM月付1.99美元起,支持支付宝/PayPal

CloudCone是一家成立于2017年的国外VPS主机商,提供独立服务器租用和VPS主机,其中VPS基于KVM架构,多个不同系列,譬如常规VPS、大硬盘VPS等等,数据中心在洛杉矶MC机房。商家2021年Flash Sale活动继续,最低每月1.99美元,支持7天退款到账户,支持使用PayPal或者支付宝付款,先充值后下单的方式。下面列出几款VPS主机配置信息。CPU:1core内存:768MB...

www.38.com为你推荐
vc组合维生素C和维生素E混合胶囊有用吗,还是分开的好?杰景新特杰德特这个英雄怎么样冯媛甑冯媛甄多大啊?www.qq530.com谁能给我一个听歌的网站?www.119mm.comwww.993mm+com精品集!789se.comwuwu8.com这个站长是谁?kb123.netwww.zhmmjyw.net百度收录慢?ww.43994399小游戏立即打开玩邯郸纠风网邯郸市信访局地址剑影绝杀三国战记武将争霸中鬼剑士,曹操,吕布等人的大绝杀怎么发呀,速求
windows虚拟主机 国外vps主机 主机测评 安云加速器 sub-process win8升级win10正式版 debian源 网站被封 河南服务器 ca4249 hostker 服务器托管什么意思 免费phpmysql空间 闪讯官网 阿里云手机官网 卡巴斯基官网下载 .htaccess 美国主机 海外加速 web服务器有哪些 更多